Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15348507 | 0.88 | ERN1 (0.58) | ERN1TRPV4ALDH1A1TDP1HPGD | |
| SCHEMBL16632430 | 0.83 | PRKDC (0.52) | ERN1TRPV4ALDH1A1TDP1HPGD | |
| SCHEMBL1251300 | 0.82 | ERN1 (0.53) | ERN1TRPV4ALDH1A1TDP1HPGD | |
| SCHEMBL5729812 | 0.81 | ERN1 (0.41) | ERN1ALDH1A1TDP1HPGDMEN1 | |
| SCHEMBL1225577 | 0.80 | ERN1 (0.52) | ERN1ALDH1A1TDP1MEN1MAPT | |
| SCHEMBL1478624 | 0.79 | ERN1 (0.50) | ERN1TRPV4ALDH1A1TDP1MEN1 | |
| SCHEMBL15348481 | 0.79 | ERN1 (0.66) | ERN1TRPV4ALDH1A1TDP1HPGD | |
| SCHEMBL4099200 | 0.78 | ERN1 (0.65) | ERN1ALDH1A1TDP1HPGDPRKDC | |
| SCHEMBL2027384 | 0.77 | ERN1 (0.58) | ERN1ALDH1A1TDP1HPGDMEN1 | |
| SCHEMBL9279963 | 0.77 | ERN1 (0.51) | ERN1ALDH1A1TDP1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20240101563-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-03-28 | — | — | US | disclosed |
| WO-2024023266-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101563-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | ERN1 366/4885TRPV4 737/4885MAP3K14 753/4885 |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | ERN1 3386/4885TRPV4 156/4885MAP3K14 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.